Avenue signs license agreement with AnnJi Pharmaceutical for AJ201
Avenue Therapeutics has signed an exclusive license agreement with Taiwanese clinical-stage drug company AnnJi Pharmaceutical to develop and commercialise the first-in-class clinical asset, AJ201.